Casopitant (INNTooltip International Nonproprietary Name),[1]: 208 former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting.[2][3] It was under development by GlaxoSmithKline.[2] In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary.[2][4] However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.[5]
^"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List56" (PDF). World Health Organization. 2006. Retrieved 17 November 2016.
^ abcName, Drug (25 December 2021). "Casopitant". AdisInsight. Retrieved 21 August 2022.
^Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer Journal. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612. S2CID 43224257.
^"GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Archived from the original (PDF) on 15 October 2009. Retrieved 21 December 2009.
^Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H (July 2022). "Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry". Pharmacopsychiatry. 55 (4): 193–202. doi:10.1055/a-1714-9097. PMC 9259184. PMID 35045580.
Casopitant (INNTooltip International Nonproprietary Name),: 208 former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist...
Aprepitant (Emend) is a commercially available NK1 receptor antagonist Casopitant is an investigational NK1 receptor antagonist Rolapitant (Varubi) another...
withdrawn. Subsequently, other trials with NK1 receptor antagonists, casopitant and orvepitant, have shown promising results. Beyond suggestions that...
antiemetic effect in both acute and especially in delayed phases of emesis. Casopitant, netupitant and rolapitant are some newer additions in this group. Rolapitant...